Cogent Biosciences will present at the J.P. Morgan Healthcare Conference on January 13, 2026, discussing precision therapies.
Quiver AI Summary
Cogent Biosciences, Inc. has announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. The presentation will be available via a live webcast, with a replay accessible afterward for 30 days. The company specializes in precision therapies for genetically defined diseases, with its lead clinical program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors. Cogent is also progressing in a Phase 1 study of a new FGFR2/3 inhibitor and is developing therapies for various genetic mutations. The company operates out of Waltham, MA and Boulder, CO. More information can be found on their website or social media platforms.
Potential Positives
- Cogent Biosciences will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, showcasing the company's advancements and potentially attracting investor interest.
- The company's focus on developing precision therapies for genetically defined diseases demonstrates a commitment to addressing unmet medical needs, particularly with their lead program targeting systemic mastocytosis and gastrointestinal stromal tumors.
- Bezuclastinib, the company's advanced clinical program, represents an innovative treatment approach for serious diseases driven by specific genetic mutations, highlighting Cogent's role in precision medicine.
- The ongoing Phase 1 study of a novel FGFR2/3 inhibitor signifies Cogent's continued investment in research and development, positioning the company for future growth and innovation in biotechnology.
Potential Negatives
- None
FAQ
What is the date and time of Cogent Biosciences' presentation at the J.P. Morgan Healthcare Conference?
The presentation will take place on January 13, 2026, at 8:15 a.m. PT / 11:15 a.m. ET.
How can I access the live webcast of the conference presentation?
The live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com.
Will there be a replay of the webcast available after the event?
Yes, a replay of the webcast will be available roughly two hours after the event and will be archived for 30 days.
What is the main focus of Cogent Biosciences, Inc.?
Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, particularly targeting specific mutations.
Where is Cogent Biosciences headquartered?
Cogent Biosciences is based in Waltham, Massachusetts, and Boulder, Colorado.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COGT Insider Trading Activity
$COGT insiders have traded $COGT stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $COGT stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 2,777,777 shares for an estimated $24,999,993
- JOHN EDWARD ROBINSON (Chief Scientific Officer) sold 90,000 shares for an estimated $3,486,600
- JESSICA SACHS (Chief Medical Officer) sold 82,642 shares for an estimated $3,198,245
- JOHN L. GREEN (Chief Financial Officer) sold 77,000 shares for an estimated $2,978,360
- EVAN KEARNS (Chief Legal Officer) sold 65,000 shares for an estimated $2,515,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COGT Hedge Fund Activity
We have seen 126 institutional investors add shares of $COGT stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 7,196,051 shares (-69.5%) from their portfolio in Q3 2025, for an estimated $103,335,292
- DEERFIELD MANAGEMENT COMPANY, L.P. added 6,412,903 shares (+242.9%) to their portfolio in Q3 2025, for an estimated $92,089,287
- FMR LLC added 5,329,795 shares (+31.2%) to their portfolio in Q3 2025, for an estimated $76,535,856
- COMMODORE CAPITAL LP added 4,938,836 shares (+213.7%) to their portfolio in Q3 2025, for an estimated $70,921,684
- POINT72 ASSET MANAGEMENT, L.P. removed 3,674,091 shares (-74.8%) from their portfolio in Q3 2025, for an estimated $52,759,946
- VESTAL POINT CAPITAL, LP removed 3,080,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $44,228,800
- FAIRMOUNT FUNDS MANAGEMENT LLC added 2,777,777 shares (+44.6%) to their portfolio in Q3 2025, for an estimated $39,888,877
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$COGT Analyst Ratings
Wall Street analysts have issued reports on $COGT in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 12/19/2025
- Leerink Partners issued a "Outperform" rating on 11/10/2025
- Raymond James issued a "Strong Buy" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $COGT, check out Quiver Quantitative's $COGT forecast page.
$COGT Price Targets
Multiple analysts have issued price targets for $COGT recently. We have seen 8 analysts offer price targets for $COGT in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $52.0 on 01/06/2026
- Anupam Rama from JP Morgan set a target price of $67.0 on 12/19/2025
- Colleen Kusy from Baird set a target price of $34.0 on 11/11/2025
- Andrew Berens from Leerink Partners set a target price of $50.0 on 11/10/2025
- Laura Prendergast from Stifel set a target price of $16.0 on 10/16/2025
- Chris Raymond from Raymond James set a target price of $30.0 on 09/03/2025
- Charles Zhou from Guggenheim set a target price of $20.0 on 08/25/2025
Full Release
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at
www.cogentbio.com
. Follow Cogent Biosciences on social media:
X
(formerly known as Twitter) and
LinkedIn
. Information that may be important to investors will be routinely posted on our website and
X
.
Contact:
Christi Waarich
Senior Director, Investor Relations
[email protected]
617-830-1653
